SUNPHARMA
Sun Pharmaceutical Industries Limited
NSELast Traded Price
₹1799.2
-40.8 (-2.21%)
Open
₹1844.3
High
₹1852.8
Low
₹1785.3
Prev Close
₹1844.3
Industry
Pharmaceuticals
Market Cap
432720.06 Cr
Filing History
Recent corporate announcements and filings for SUNPHARMA
Business Update
Positive
2026-05-29 20:01
Sun Pharma guided for high single-digit consolidated top-line growth and 6-7% R&D spend as a percentage of sales for FY27, with an expected effective tax rate of around 25%. Growth is anticipated from continued strong performance in Global Innovative Medicines, including ILUMYA, Odomzo, Cequa, Winlevi, and recent launches like UNLOXCYT and LEQSELVI. India formulations are also expected to maintain strong performance with new product introductions such as semaglutide. The company is addressing compliance issues in its generics business with a new sterile-only facility in Madhya Pradesh to expand capacity for global markets. The acquisition of Organon is expected to be completed in Q4 FY27.
Business Update
Neutral
2026-05-27 16:00
Sun Pharmaceutical Industries Limited announced the schedule of upcoming analyst/institutional investor meetings on June 1, 2, and 4, 2026, in Mumbai. These include BofA India Conference-2026, Morgan Stanley's India Investment Forum 2026, and Citi India Conference 2026. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed at these meetings.
Ownership
Neutral
2026-05-26 21:18
Sun Pharmaceutical Industries Limited submitted an application to stock exchanges on May 26, 2026, seeking reclassification from the 'Promoter Group' category to 'Public' category, as per Regulation 31A of SEBI Listing Regulations. This follows prior intimations on May 14 and May 22, 2026.
Business Update
Positive
2026-05-26 18:25
Sun Pharmaceutical Industries Limited will present pivotal long-term follow-up data on UNLOXCYT (cosibelimab-ipdl) at the ASCO® 2026 Annual Meeting on May 31, 2026. The data reported an objective response rate of 50%, including 27% complete responses, in patients with locally advanced cutaneous squamous cell carcinoma. Responses were durable over 31 months, and the drug showed a manageable safety profile with only one patient experiencing a Grade >3 immune-related adverse event.
Business Update
Neutral
2026-05-25 14:16
Sun Pharmaceutical Industries Limited announced an Analyst/Institutional Investor Meeting scheduled for May 27, 2026, with 360 ONE Capital(B&K) at their 16th Annual Investor Conference - TRINITY INDIA 2026 in Mumbai. The meeting will be physical, including both group and one-on-one sessions. The company clarified that no Unpublished Price Sensitive Information will be disclosed.
Business Update
Neutral
2026-05-22 20:56
Sun Pharmaceutical Industries Limited announced on May 22, 2026, the availability of the audio recording for its investor earnings call held today. The recording can be accessed on the company's website, following the intimation dated May 13, 2026, regarding the earnings call.
Governance
Neutral
2026-05-22 18:19
Sun Pharmaceutical Industries Limited's Board of Directors, at its meeting on May 22, 2026, approved requests for the reclassification of certain promoter group individuals to the 'Public' category, pending SEBI approvals as per Regulation 31A. Additionally, the board approved and adopted the revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, which will be effective from June 01, 2026.
Financials
Positive
2026-05-22 15:06
Sun Pharmaceutical Industries Limited's Board of Directors, at its meeting on May 22, 2026, approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of Rs. 5/- per equity share for FY 2025-26, subject to shareholder approval. The auditors issued an unmodified opinion on the financial results. A press release and earnings presentation for the period were also approved.
Financials
Positive
2026-05-22 15:01
Consolidated Revenue ₹14,611.79 Cr vs ₹12,958.84 Cr (▲12.75% YoY), EBITDA ₹3,954.20 Cr vs ₹3,716.09 Cr (▲6.41% YoY), PAT ₹2,714.03 Cr vs ₹2,149.88 Cr (▲26.24% YoY). EBITDA Margin 27.06% vs 28.68% (▼162bps). The Board also recommended a final dividend of ₹5/- per equity share for FY 2025-26.
Financials
Positive
2026-05-22 14:46
Sun Pharmaceutical Industries Limited reported consolidated financials for the quarter ended March 31, 2026. Consolidated Revenue stood at ₹14,611.8 Cr vs ₹12,958.8 Cr (▲12.8% YoY), EBITDA was ₹3,954.2 Cr vs ₹3,354.4 Cr (▲17.9% YoY), and PAT was ₹2,714.0 Cr vs ₹2,149.9 Cr (▲26.2% YoY). EBITDA Margin expanded by 118bps, from 25.9% to 27.1%. The Board also recommended a final dividend of Rs. 5/- per equity share for FY 2025-26.
Ownership
Neutral
2026-05-14 12:27
Sun Pharmaceutical Industries Limited has received requests from Mr. Sudhir Vrundavandas Valia, Mrs. Raksha Sudhir Valia, and Mrs. Krishna Vrundavandas Valia (members of the Promoter Group) for reclassification of their 4,31,75,371 shares (1.80% of total shares) to the 'Public' category. The requests will be examined and presented to the Board for approval.
Financials
Neutral
2026-05-13 17:45
Sun Pharmaceutical Industries Limited announced it will release its financial results for the fourth quarter ended 31 March 2026, on 22 May 2026. An earnings call to discuss the results is scheduled for 06:30 PM IST on the same day.
Governance
Positive
2026-05-12 18:51
Sun Pharmaceutical Industries Limited announced the appointment of Dr. Andreas Busch as an Independent Director for a five-year term effective May 12, 2026. Ms. Rama Bijapurkar will retire as an Independent Director on May 20, 2026, upon completion of her term. Additionally, Ms. Satyavati Berera has been appointed as a member of the Audit Committee and Risk Management Committee, effective May 12, 2026.
Governance
Neutral
2026-05-08 19:52
Sun Pharmaceutical Industries Limited announced the completion of its postal ballot process, initiated on April 07, 2026, with remote e-voting starting April 09, 2026. Shareholders duly approved the resolution. Ms. Satyavati Berera (DIN: 05002709) has been appointed as an Independent Director for a five-year term, effective May 08, 2026. Voting results are available on the company's website.
Business Update
Neutral
2026-05-07 18:33
CRISIL and ICRA reaffirmed Sun Pharma's long-term credit rating at 'AAA' and short-term at 'A1+'. CRISIL, however, placed the long-term rating on 'Rating Watch with Developing Implications' following the announcement of the Organon & Co. acquisition on April 27, 2026. ICRA reaffirmed its 'AAA(Stable)' rating, taking note of the acquisition.
Business Update
Positive
2026-05-05 23:18
Sun Pharmaceutical Industries Ltd. announced the acquisition of Organon & Company for an equity value of $3.99 billion and an enterprise value of $11.75 billion. The transaction will be financed partly by Sun's cash surplus ($2-2.5 billion) and bank financing, resulting in a net debt to EBITDA of 2.3x, which management aims to repay quickly given the combined entity's projected $2-2.5 billion annual free cash flow. The acquisition is expected to be EPS accretive from the beginning, with approximately $350 million in cost synergies anticipated within 2-4 years. This move is deemed transformative, positioning Sun Pharma as a top 25 global pharma company with combined revenues of $12.4 billion, strengthening its presence in innovative medicines, women's health (number three globally), and biosimilars (number seven), and expanding its commercial footprint to over 150 markets including a significant entry into China.
Business Update
Positive
2026-04-27 18:00
Sun Pharmaceutical Industries Limited announced the availability of the investor call audio recording held on April 27, 2026, concerning the acquisition of Organon & Co. The recording can be accessed on the company's website.
Business Update
Positive
2026-04-27 06:14
Sun Pharmaceutical Industries Limited announced an investor call on April 27, 2026, at 08:00 am IST to discuss the acquisition of Organon & Co. The call will provide updates related to the announced asset.
Business Update
Positive
2026-04-27 05:25
Sun Pharma announced a definitive agreement to acquire Organon for US$ 14.00 per share, with an enterprise valuation of US$ 11.75 billion. The deal is expected to create a stronger global pharma company with combined revenue of US$ 12.4 billion, and close in early 2027.
Business Update
Positive
2026-04-24 13:24
Sun Pharmaceutical Industries Limited announced the incorporation of a 100% owned subsidiary, Sun Pharma America, Inc., in the United States of America on April 23, 2026, for internal group structuring.
Routine
Neutral
2026-04-17 22:48
New Filing detected. See link for details.
Business Update
Neutral
2026-04-10 16:11
Sun Pharma clarified a moneycontrol.com news item dated April 10, 2026, stating that reports of the 'Organon deal entering final stage' causing a 4% slip are speculative and not material information requiring disclosure.
Routine
Neutral
2026-04-10 11:13
New Filing detected. See link for details.
Governance
Neutral
2026-04-07 15:51
Sun Pharmaceutical Industries Limited is seeking shareholder approval via Postal Ballot/E-voting for the appointment of Ms. Satyavati Berera as an Independent Director. She will replace Ms. Rama Bijapurkar, whose term concludes on May 20, 2026. The e-voting period is from April 9, 2026, to May 8, 2026.
Routine
Neutral
2026-04-06 16:55
Sun Pharmaceutical Industries Limited submitted a Confirmation Certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate from MUFG Intime India Pvt. Ltd. confirms proper handling and listing of securities received for dematerialisation.
Governance
Positive
2026-04-04 16:01
Sun Pharmaceutical Industries Limited announced the appointment of Ms. Satyavati Berera, former COO of PwC India, as an Independent Director for a five-year term, subject to shareholder approval. Her extensive experience is expected to strengthen the Board's independence and governance.
Business Update
Neutral
2026-03-28 00:28
Sun Pharma announced mixed clinical updates. Fibromun's Phase II FLASH and GLIOSTAR studies for sarcoma and glioblastoma missed primary endpoints, but a Phase III trial for FIBROSARC-2 is planned. Nidlegy showed excellent Phase II results (52.6% complete response in BCC) leading to four new registrational studies for skin cancers, despite a prior EMA withdrawal.
Business Update
Positive
2026-03-27 21:14
Sun Pharma announced it will present 14 abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting from March 27-31, 2026. The presentations will highlight advances in research for Alopecia Areata, Psoriasis, and Acne, underscoring the company's leadership in dermatology and immunology with drugs like ILUMYA, LEQSELVI, and WINLEVI.
Routine
Neutral
2026-03-25 20:42
Sun Pharmaceutical Industries Limited announced the closure of its trading window from April 01, 2026, until 48 hours after the declaration of audited financial results for the financial year ended March 31, 2026. The Board Meeting date will be communicated later.
Business Update
Positive
2026-03-21 11:58
Sun Pharmaceutical Industries Limited announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India on March 21, 2026. These products are indicated for chronic weight management and type 2 diabetes mellitus, priced significantly lower for greater affordability.
Governance
Positive
2026-03-17 18:31
Sun Pharma seeks shareholder approval via e-voting (March 19 - April 17, 2026) for Cost Auditor's remuneration, re-appointment of Dr. Pawan Goenka as Independent Director, and amending its MOA for renewable power generation, enhancing ESG and operational efficiency.
Routine
Neutral
2026-03-17 10:39
Sun Pharmaceutical Industries Limited launched a Shareholder Satisfaction Survey on RTA services, open from March 17 to March 31, 2026. It seeks feedback from shareholders who availed RTA services between April 1, 2025, and December 31, 2025, to improve service quality.
Business Update
Positive
2026-03-16 16:24
Sun Pharma announced US FDA acceptance of a Supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active Psoriatic Arthritis. An FDA decision is expected by October 29, 2026.
Business Update
Positive
2026-02-24 15:44
Sun Pharmaceutical Industries Limited submitted an Investor Presentation dated February 2026. This presentation provides an overview of the company's business operations, R&D, manufacturing, and key financials, aimed at informing investors.
Business Update
Neutral
2026-02-03 18:53
Sun Pharmaceutical Industries Limited informed about its upcoming schedule of analyst/institutional investor meetings with various firms like Nuvama, Systematix, and Kotak Securities from February 9-24, 2026. No Unpublished Price Sensitive Information will be disclosed.